JOHN D. LOVE, District Judge.
Before the Court is Plaintiff Realtime Data, LLC's ("Realtime" or "Plaintiff") Motion to Strike Portions of the Invalidity Expert Reports of Dr. Clifford Reader and Dr. H.V. Jagadish (Doc. No. 167). Defendants EchoStar Corporation ("EchoStar") and Hughes Network Systems, LLC ("Hughes") ("EchoStar" and "Hughes" are collectively known as "Defendants") have filed a Response (Doc. No. 202), to which Plaintiff has filed a Reply (Doc. No. 216), and Defendants have filed a Sur-Reply (Doc. No. 232). Upon consideration of the Parties' arguments, Plaintiff's Motion (Doc. No. 167) is
Plaintiff alleges that Defendants infringe certain claims of U.S. Patent No. 9,054,728 ("the '728 Patent") and U.S. Patent No. 8,502,707 ("the '707 Patent").
Federal Rule of Civil Procedure 26(a)(2)(B) provides several requirements for disclosures expert witnesses must include as part of their written reports. Fed. R. Civ. P. 26(a)(2)(B). Among these requirements is, "a complete statement of all opinions the witness will express and the basis and reasons for them." Fed. R. Civ. P. 26(a)(2)(B)(i). Federal Rule of Civil Procedure 37(c)(1), discusses sanctions that may be imposed on a party failing to comply with the disclosure requirements set forth in Rule 26. Specifically, a court may prohibit improperly withheld information from being used, "to supply evidence on a motion, at a hearing, or at a trial, unless the failure was substantially justified or is harmless." Fed. R. Civ. P. 37(c)(1).
Federal Rule of Evidence 702 provides standards for the admissibility of expert testimony. Specifically, an expert witness may provide opinion testimony if "(a) the expert's scientific, technical, or other specialized knowledge will help the trier of fact to understand the evidence or to determine a fact in issue; (b) the testimony is based on sufficient facts or data; (c) the testimony is the product of reliable principles and methods; and (d) the expert has reliably applied the principles and methods to the facts of the case." Fed. R. Evid. 702.
Rule 702 requires a district court to make a preliminary determination, when requested, as to whether the requirements of the rule are satisfied with regard to a particular expert's proposed testimony. Kumho Tire Co. v. Carmichael, 526 U.S. 137, 149, 119 S.Ct. 1167, 1175, 143 L. Ed. 2d 238 (1999); Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 592-93, 113 S.Ct. 2786, 2796, 125 L. Ed. 2d 469 (1993). District courts are accorded broad discretion in making Rule 702 determinations of admissibility. Kumho Tire Co., 526 U.S. at 152 ("[T]he trial judge must have considerable leeway in deciding in a particular case how to go about determining whether particular expert testimony is reliable."). Although the Fifth Circuit
Plaintiff seeks to strike portions of Dr. Jagadish's and Dr. Reader's invalidity reports on two grounds: (1) inclusion of, "boilerplate assertions of obviousness;" and (2) inclusion of, "theories of invalidity on patents and patent claims no longer asserted," by Plaintiff. (Doc. No. 167, at 3-9.) Defendants offer no argument in response to Plaintiff's first ground. (Doc. No. 202.) With respect to Plaintiff's second ground, Defendants argue the invalidity theories objected to by Plaintiff relate to Defendants' declaratory judgment counterclaims of invalidity. (Doc. No. 202, at 5-15.)
Both Dr. Jagadish and Dr. Reader include charts as an appendix to their reports that discuss how they contend each prior art reference reads on each element of the claims they allege are invalid. (Doc. No. 167, Ex. B and C.) At the end of each section discussing a particular claim element, Plaintiff alleges both experts include a "boilerplate" paragraph regarding obviousness. (Doc. No. 167, at 3-6.) Specifically, Plaintiff claims the two experts' reports combined contain 314 repetitions of the following template:
(Doc. No. 167, at 4.)
Relying primarily upon Karl Storz Endoscopy-Am., Inc. v. Stryker Corp.
Defendants have offered no response in opposition to Plaintiff's arguments. Accordingly, Plaintiff's Motion is
At this time, Plaintiff has voluntarily elected to only pursue infringement claims based on claims 1, 4, 20, and 24-25 of U.S. Patent No. 9,054,728 ("the '728 Patent") and claim 16 of U.S. Patent No. 8,502,707 ("the '707 Patent") at trial.
Plaintiff seeks to strike discussion of invalidity of all Patents and claims no longer being asserted by Plaintiff. (Doc. No. 167, at 6-9.) Plaintiff argues that Defendants' inclusion of these Patents and claims: (1) violates the Court's Order Focusing Patent Claims and Prior Art to Reduce Costs; and (2) lacks subject matter jurisdiction as a "case or controversy" no longer exists for unasserted patent claims. (Doc. No. 167, at 6-9.) In response, Defendants argue that: (1) the Order Focusing Patent Claims and Prior Art to Reduce Costs does not implicate declaratory judgment of counterclaims; and (2) the Court still maintains jurisdiction over the invalidity counterclaims. (Doc. No. 202, at 5-15.)
For a court to hold subject matter jurisdiction under the Declaratory Judgment Act, there must be a, "substantial controversy, between parties having adverse legal interests, of sufficient immediacy and reality to warrant the issuance of a declaratory judgment." MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118, 127, 127 S.Ct. 764, 771, 166 L. Ed. 2d 604 (2007) (quoting Maryland Cas. Co. v. Pac. Coal & Oil Co., 312 U.S. 270, 273, 61 S.Ct. 510, 512, 85 S.Ct. 826 (1941)). Courts, however, hold, "unique and substantial discretion," in deciding whether to exercise discretionary dismissal of a declaratory judgment action based upon equitable, prudential, and policy grounds. Id. at 136-37 (quoting Wilton v. Seven Falls Co., 515 U.S. 277, 286, 115 S.Ct. 2137, 2142, 132 L. Ed. 2d 214 (1995)).
Plaintiff has granted a covenant not to sue on some, but not all of the dropped previously asserted claims.
"[I]n patent cases, the existence of a `case or controversy must be evaluated on a claimby-claim basis.'" Streck, Inc. v. Research & Diagnostic Sys., Inc., 665 F.3d 1269, 1281 (Fed. Cir. 2012) (quoting Jervis B. Webb Co. v. S. Sys., Inc., 742 F.2d 1388, 1399 (Fed. Cir. 1984)). Furthermore, "jurisdiction must exist `at all stages of review, not merely at the time the complaint [was] filed.'" Id. at 1282 (quoting Benitec Australia, Ltd. v. Nucleonics, Inc., 495 F.3d 1340, 1345 (Fed. Cir. 2007)). The party seeking a declaratory judgment bears the burden of establishing the existence of an actual case or controversy. Id.
A case or controversy does not automatically exist because a competitor seeks to mount a validity challenge. Id. at 1284. Indeed, the Federal Circuit has found a court may lack jurisdiction to hear a declaratory judgment action invalidity counterclaim—even in the absence of a covenant not to sue—when a patentee voluntarily narrows the scope of asserted claims prior to a dispositive ruling by the court. Id.; Allergan, Inc. v. Sandoz, Inc., 681 F. App'x 955, 962-64 (Fed. Cir. 2017); Fox Grp., Inc. v. Cree, Inc., 700 F.3d 1300, 1308 (Fed. Cir. 2012). In the instant case, Plaintiff has voluntarily elected to not pursue at trial several previously asserted claims. (Doc. No. 167, Ex. G; Doc. No. 248.) A patentee's voluntary withdraw of previously asserted patent claims is, "akin to either a Federal Rule of Civil Procedure 15 amendment to the complaint, . . . or a Rule 41(a) voluntary dismissal of claims without prejudice."
Furthermore, equitable considerations support declining to exercise jurisdiction to hear the declaratory judgment invalidity counterclaim. MedImmune, Inc., 549 U.S. at 136-37. This Court has recognized that, "[r]eduction of claims and related invalidity defenses are an important case management tool." VirnetX Inc. v. Cisco Sys., Inc., No. 6:10-cv-00417, 2014 WL 12605380, at *5 (E.D. Tex. Mar. 28, 2014); see also Metaswitch Networks Ltd., No. 2:14-cv-00744-JRG-RSP, 2016 WL 1426451, at *1 (discussing the court's reliance upon the parties to act in good faith to voluntarily narrow the scope of the case). However, "[f]or the process to work there must be fairness—both claims and related invalidity defenses need to be dismissed on the same basis, either with or without prejudice." VirnetX Inc., No. 6:10-cv-00417, 2014 WL 12605380, at *5. As discussed, supra, Plaintiff's voluntary election not to pursue certain claims at trial operates as a dismissal without prejudice. Accordingly, considerations of equity and judicial economy would support dismissing Defendants' invalidity counterclaims on the same basis.
As the Court no longer exercises jurisdiction over Defendants' invalidity counterclaims relating to patent claims Plaintiff has voluntarily elected not to pursue at trial, expert testimony on the invalidity of these patent claims is no longer helpful to the trier of fact, "to understand the evidence or to determine a fact in issue." Fed. R. Evid. 702(a). Accordingly, the Court finds it appropriate that this testimony be
For the reasons stated herein, the Court